Primidone

BRAND NAMES

• Mysoline (an anticonvulsant/barbiturate medication)

• Lepimidone (in some countries) 

• Primaclone (availability varies by region) 

MECHANISM OF ACTION 

Primidone exerts its anticonvulsant effects through its active metabolites, mainly phenobarbital and phenylethylmalonamide (PEMA). Phenobarbital enhances inhibitory neurotransmission by binding to the GABA-A receptor complex, increasing the duration of chloride channel opening and thereby strengthening GABA-mediated neuronal inhibition. This leads to hyperpolarization of neurons and reduced excitability in the central nervous system.

PHARMACOKINETICS

Absorption

Primidone is well absorbed from the gastrointestinal tract following oral administration, with high bioavailability. Peak plasma concentrations are typically reached within 2 to 4 hours after dosing. Food does not significantly affect the overall extent of absorption but may slightly delay the rate.

Distribution

Primidone has an apparent volume of distribution of approximately 0.6–1.0 L/kg, indicating wide distribution into body tissues, including the central nervous system.

Metabolism

Primidone is partially metabolized in the liver through oxidative pathways to its two major active metabolites: phenobarbital and phenylethylmalonamide (PEMA).

Elimination

Primidone is eliminated through both renal excretion of the unchanged drug and hepatic metabolism to active metabolites, which are also primarily excreted by the kidneys. Approximately 15–25% of primidone may be excreted unchanged in urine.

PHARMACODYNAMICS 

Primidone produces its pharmacological effects primarily through its active metabolites, phenobarbital and phenylethylmalonamide (PEMA). Phenobarbital enhances the inhibitory action of GABA in the central nervous system by binding to the GABA-A receptor complex, increasing the duration of chloride channel opening, which leads to neuronal hyperpolarization and reduced excitability. This results in a generalized depressant effect on abnormal neuronal firing. In addition, primidone and its metabolites reduce repetitive neuronal discharge by modulating sodium channel activity, stabilizing neuronal membranes. These combined actions suppress seizure activity and help control essential tremor by decreasing excessive neuronal excitability.

ADMINISTRATION

Primidone is administered orally, usually in the form of tablets. Treatment is typically started at a low dose and gradually increased to reduce the risk of side effects such as sedation, dizziness, and nausea. It is commonly taken two to three times daily, depending on the prescribed regimen and patient response. Primidone may be taken with food or milk to improve gastrointestinal tolerance. Long-term therapy requires careful dose titration and regular monitoring, especially during initiation, due to variability in individual response and the formation of active metabolites that contribute to its prolonged effect.

DOSAGE AND STRENGTH

Primidone is available in tablet form, commonly in strengths of 50 mg and 250 mg. In some regions, other strengths may also be available depending on manufacturer.

The dosage varies based on the condition being treated (epilepsy or essential tremor), patient age, and clinical response. For adults, therapy is usually initiated at a low dose (e.g., 50–125 mg at bedtime) and gradually increased every few days or weeks to minimize side effects. Maintenance doses typically range from 250 mg to 750 mg per day, divided into 2–3 doses, though some patients may require higher doses for seizure control.

DRUG INTERACTIONS

Primidone has several clinically important drug interactions, mainly due to its conversion to phenobarbital, a potent enzyme inducer. It can increase the metabolism and reduce the effectiveness of many drugs, including oral contraceptives, anticoagulants (e.g., warfarin), corticosteroids, doxycycline, and some antiretroviral and antifungal agents.

FOOD INTERACTIONS

Primidone does not have major direct food–drug interactions, and its absorption is generally not significantly affected by food. However, taking it with food or milk may help reduce gastrointestinal side effects such as nausea or stomach upset. Alcohol should be strictly avoided because it can enhance the central nervous system depressant effects, leading to increased drowsiness, dizziness, and impaired coordination.

CONTRAINDICATIONS

Primidone is contraindicated in patients with a known hypersensitivity to primidone, phenobarbital, or other barbiturates. It should be avoided in individuals with acute intermittent porphyria, as barbiturates can precipitate life-threatening attacks.

SIDE EFFECTS 

• Sedation (drowsiness, sleepiness) 

• Dizziness or lightheadedness 

• Ataxia (poor coordination, unsteady gait) 

• Nausea and vomiting (especially at treatment start) 

• Fatigue and weakness 

• Blurred vision or nystagmus 

• Cognitive impairment (slowed thinking, poor concentration) 

• Mood changes (irritability or depression) 

• Skin rash (rare hypersensitivity reaction) 

• Blood dyscrasias (rare: anemia, leukopenia, thrombocytopenia) 

• Dependence or tolerance with long-term use 

• Paradoxical excitement or agitation (rare)

OVER DOSE

Primidone overdose results in excessive central nervous system depression due to accumulation of primidone and its active metabolite phenobarbital. Early symptoms include marked drowsiness, confusion, slurred speech, nausea, vomiting, and dizziness. As toxicity increases, patients may develop severe ataxia, loss of consciousness, respiratory depression, hypotension, and coma.

TOXICITY

Primidone toxicity is primarily due to excessive levels of primidone and its active metabolite phenobarbital, leading to profound central nervous system depression. Clinical features include severe drowsiness, confusion, slurred speech, impaired coordination, nystagmus, and ataxia. In more serious cases, toxicity can progress to respiratory depression, hypotension, hypothermia, coma, and potentially death.